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  25 
Abstract 26 
Background: The emergence and spread of carbapenem-resistant Enterobacteriaceae 27 
(CRE) is a global health problem due to its high mortality and limited treatment options. 28 
Combination antimicrobial therapy is reported to be effective against CRE in vitro; 29 
however, its efficacy in vivo has not been thoroughly evaluated. Thus, this study 30 
assessed the efficacy of combination therapy of meropenem (MEPM) and amikacin 31 
(AMK) in a carbapenem-resistant Klebsiella pneumoniae (CR-Kp) mouse model of 32 
pneumonia. 33 
Materials and Methods: Agar-based bacterial suspension of CR-Kp clinical isolates was 34 
inoculated into the trachea of BALB/c mice. Treatment was initiated 6 h post infection, 35 
with 100 mg/kg MEPM every 6 h, 100 mg/kg AMK every 12 h, or in combination; 36 
survival was evaluated for 7 days. The number of viable bacteria in the lungs, lung 37 
histopathology, and neutrophil counts in broncho-alveolar lavage fluid (BALF) were 38 
evaluated 42 h after infection. 39 
Results: All mice in the untreated control group died in 48 hours, while all the mice in 40 
treatment groups survived past 7 days following infection. The bacterial count in the 41 
lungs (log10 CFU/mL, mean ± SEM) in the combination group (2.00 ± 0.00) decreased 42 
significantly compared to that in control (10.19 ± 0.11, p<0.0001), MEPM (6.38 ± 0.17, 43 
p<0.0001), and AMK (6.17 ± 0.16, p<0.0001) groups. BALF neutrophil count reduced 44 
only in the combination therapy group. Combination therapy prevented the progression 45 
of lung inflammation, including alveolar neutrophil infiltration and hemorrhage. 46 
Conclusions: This study demonstrates in vivo efficacy of MEPM and AMK combination 47 
therapy against CR-Kp pneumonia. 48 
 49 
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1. Introduction 63 
Emergence of carbapenem-resistant Enterobacteriaceae (CRE) has been considered one 64 
of the major global health problems that require immediate and appropriate actions [1,2]. 65 
Nevertheless, the global spread of CRE is accelerating. A recent systematic review 66 
revealed that the resistance rates to imipenem and meropenem in Enterobacteriaceae are 67 
steadily increasing in Asia (from 0.5% and 0.3% in 2000-2004 to 1.9% and 2.4% in 2009-68 
2011, respectively). Among the three most commonly isolated Enterobacteriaceae, 69 
Klebsiella pneumoniae has demonstrated the highest resistance rates [3]. 70 
CRE infections possess a high impact on mortality, which makes CRE an even more 71 
urgent problem. A previous study reported that infections caused by CRE have high 72 
mortality rates, ranging from 18% to 48% [4]. The mortality rate is higher especially in 73 
immunocompromised patients, who are prone to CRE colonization [5]. Therefore, the 74 
establishment of appropriate and robust antimicrobial treatment is strongly required. 75 
Antibiotic combination therapy is considered to be superior to monotherapy for treatment 76 
of CRE infections, due to reduction in use of inappropriate initial antimicrobial therapy, 77 
the potential synergistic effects, and suppression of emerging resistance [6]. A recent 78 
clinical observational study revealed that combination therapy with two or more active 79 
agents, in vitro, was associated with lower mortality than treatment with a single active 80 
agent [7]. However, the evidence that supports the effectiveness of anti-CRE agents, 81 
colistin and tigecycline, against pneumonia is scarce. In a set of mouse pneumonia 82 
experiments, intravenously administered colistin, lacked permeability into lung tissue [8], 83 
and has been reported to be less effective against pneumonia than against other types of 84 
infection in a clinical study [9]. Tigecycline’s clinical effectiveness to pneumonia and 85 
safety are not yet studied thoroughly enough [10], and its use for treatment in pneumonia 86 
is not approved in Japan. Therefore, development of an antibiotic regimen independent 87 
of colistin or tigecycline is crucial to the treatment of pneumonia caused by CRE. Among 88 
the limited antibiotics available, carbapenem is a reasonable option when administered in 89 
combination with another active antibiotic. Daikos et al. analyzed data from 138 90 
carbapenem-resistant strains of Klebsiella pneumoniae (CR-Kp) infection in patients and 91 
found that the lowest mortality rate was observed in patients with carbapenem-based 92 
combination therapy when compared to non-carbapenem combination therapy [11]. In 93 
those regimens, aminoglycoside was the most common antibiotic accompanied by 94 
carbapenems, suggesting clinical effectiveness of the combination. The combination of 95 
carbapenems and aminoglycosides has been studied in vitro, displaying synergistic 96 
activity against CR-Kp isolates [12], but their effectiveness in the in vivo setting has not 97 
yet been studied thoroughly. 98 
In this study, we assessed the efficacy of combination therapy of meropenem (MEPM) 99 
and amikacin (AMK) in a CR-Kp mouse model of pneumonia. 100 
  101 
2. Materials and methods 102 
2.1. Bacterial strains 103 
In preliminary experiments for developing the mouse model, a total of eighteen clinically 104 
isolated CR-Kp in Nagasaki University Hospital between January 2009 and June 2015 105 
[13] were screened in four kinds of mice strains (BALB/c, C57/BL6, ddY, and ICR) by 106 
instilling saline-based inoculum into their tracheas. Among them, the strain named KP2 107 
showed the strongest pathogenicity against BALB/c, though the infection was 108 
inconsistent and lacked reproducibility. Therefore, we decided to inoculate using an agar-109 
based inoculum method, using the KP2 strain. This strain has been confirmed to have 110 
IMP-1 gene and produce carbapenemase. [13] The bacteria were stored at -80 °C in a 111 
Microbank® bead preservation system (Pro-Lab Diagnostics, Ontario, CA) until use. 112 
 113 
2.2. Antimicrobial agents 114 
MEPM, cilastatin (CS), and AMK were purchased from FUJIFILM Wako Pure Chemical 115 
Corporation (Osaka, Japan), Hangzhou APIChem Technology Co., Ltd (Hangzhou, 116 
China), and Sigma-Aldrich Co. LLC (St. Louis, MO, U.S.A.), respectively.  117 
 118 
2.3. Animals 119 
We purchased specific pathogen-free male BALB/c mice (6-7 weeks old, 18-22 g) from 120 
Japan SLC, Inc. (Shizuoka, Japan). The mice were housed in a pathogen-free environment 121 
and received sterile food and water in the Biomedical Research Center at Nagasaki 122 
University. 123 
 124 
2.4. Ethics 125 
All the experimental protocols used in this study were approved by the Ethics Review 126 
Committee for Animal Experimentation (approval number 1003310842). 127 
 128 
2.5. Antimicrobial susceptibility tests 129 
The MICs (minimum inhibitory concentration) for MEPM and AMK were determined 130 
using a microdilution method in accordance with the guidelines of the CLSI (M100, 29th 131 
ed.). 132 
 133 
2.6 Murine model of pneumonia using agar-based inoculum 134 
In order to develop a robust pneumonia model, we modified the agar-based inoculum 135 
method previously reported by Hoover et al. [14]. The KP2 strain was cultured overnight 136 
on Mueller-Hinton II agar (Becton Dickinson, Le Pont-de-Claix, France). They were 137 
suspended in sterile saline and the concentration was adjusted to 5 × 106 CFU/mL, as 138 
estimated by turbidimetry (DEN-1B Densitometer, WAKENBTECH, Kyoto, Japan). 139 
Then, the bacterial suspension was diluted with liquid Mueller-Hinton II agar to 5 × 105 140 
CFU/mL. Subsequently, 20 μL of the agar-based inoculum was inoculated through the 141 
outer sheath of the intravenous catheter (1× 104 CFU/mouse). The procedures were 142 
carried out carefully in order not to cause choking from clotted agar. For model validation, 143 
survival rate and sequential bacterial load in the lungs were analyzed. 144 
 145 
2.7. Treatment protocol 146 
Antimicrobial treatment was initiated 6 h post infection. MEPM was administered 147 
intraperitoneally at 100 mg/kg four times a day (every 6 h) combined with 100 mg/kg CS. 148 
AMK (100 mg/kg) was administered intraperitoneally twice a day (every 12 h). Treatment 149 
was continued until the evaluation time point. The doses of these antibiotics were 150 
determined according to previous studies [15,16] and concentrations that exerted a 151 
sufficient antibacterial effect were chosen for this study. For the survival analysis (n=7 152 
for each group), treatment was continued up to 120 h after inoculation and survival was 153 
checked every 6 h for 5 days. Simultaneously, bodyweights of the mice were measured 154 
twice a day until the end of the treatment. We performed the survival study and the 155 
bacteriological study separately. 156 
 157 
2.8. Bacteriological examinations 158 
For the bacteriological examinations, the infected mice of each group were sacrificed at 159 
18, 30, and 42 h post infection i.e. 12, 24, and 36 h after the initiation of therapy as well 160 
as at the end of the treatment of 5 days (n=3 to 4 for each group). Subsequently, they were 161 
dissected under aseptic conditions, blood was collected via right ventricular puncture 162 
using heparin-coated syringes. The lungs were removed, suspended in 1 mL of normal 163 
saline and homogenized with a homogenizer (T10 basic ULTRA-TURRAX®, Yamato, 164 
Fukuoka, Japan). Serial dilutions of the lungs and blood were quantitatively cultured in 165 
Mueller-Hinton II agar plates. After 12-16 h incubation, we evaluated the number of 166 
visible colonies. The lowest level of detectable counts was 1 × 102 CFU/mL.  167 
 168 
2.9. Histopathological examinations 169 
Whole lungs were removed under aseptic conditions and fixed in a 10% Formalin Neutral 170 
Buffer-Methanol Solution (Mildform® 10NM, Wako, Osaka, Japan), and then the lung 171 
tissue sections were paraffin embedded and hematoxylin and eosin (HE) stained. 172 
 173 
2.10. Bronchoalveolar lavage fluid (BALF) cell analysis 174 
BALF analysis was performed on mice different from those used for CFU determination 175 
and histopathological analysis, in order to assess inflammatory cell accumulation in the 176 
airspace. The chest was opened to expose the lungs and trachea after the mouse was 177 
sacrificed, and a disposable sterile tube (Safelet Cath® PU, NIPRO, Osaka, Japan) was 178 
inserted into the trachea. BAL was performed three times sequentially using 1.0 mL of 179 
0.9% saline each time, and the recovered fluid was pooled on ice. Total cell counts were 180 
performed by Turk staining with a hemacytometer (C-chip®, NanoEnTek Inc., Seoul, 181 
Korea), and the percentage of neutrophils was calculated using Diff-Quik staining. 182 
 183 
2.11. Statistical analysis 184 
All data were analyzed using Prism ver. 7.0e (GraphPad Software) and were expressed 185 
as mean ± standard errors of the mean (SEM). Differences between groups were 186 
examined using one-way ANOVA with Tukey’s multiple comparison test. A P value of 187 
<0.05 was considered to indicate a statistically significant difference. 188 
  189 
3. Results 190 
3.1. MICs of antimicrobial agents for KP2 191 
The MICs of MEPM and AMK for the bacterial strain KP2 were both 8 mg/L. This strain 192 
exhibits resistance to MEPM but susceptibility to AMK. 193 
 194 
3.2. Evaluation of the murine pneumonia model using agar-based CR-Kp inoculum 195 
In the evaluation of this pneumonia model, the survival rate and sequential bacterial load 196 
were analyzed. Two different bacterial concentrations of 104 and 103 CFU/mouse were 197 
compared in the survival analysis. The mortality of the 104 CFU /mouse group was higher 198 
than that of the 103 CFU /mouse group (Fig. 1A), and the bacterial load in the lungs 199 
showed a constant increase (Fig. 1B). Pathological findings were consistent with 200 
inflammation caused by a bacterial infection (Fig. 1C). 201 
 202 
3.3 Therapeutic effect of combination therapy compared to monotherapy on survival rate 203 
and change of bodyweight 204 
The survival rate of the mice is shown in Fig. 2A. Most of the mice in treatment groups 205 
survived through 5 days after infection. No statistical difference was observed in terms 206 
of survival between the three treatment groups. The change of bodyweight of the mice is 207 
shown in Fig. 2B. In all of the groups, the body weight decreased drastically just after the 208 
infection procedure. However, the decrease was suppressed in the combination group 209 
after day 2. From day 3 to 4, the body weight of combination group is statistically higher 210 
than both of the monotherapy groups (P < 0.001 vs. MEPM, P < 0.05 vs. AMK). 211 
 212 
3.4. Bacteriological examinations.  213 
The bacterial load in the lungs was counted and analyzed at each timepoint. The bacterial 214 
load started to decrease in the treatment groups after initiation of antibacterial treatment 215 
(Fig. 3A). The bacterial counts in the lungs of the control group at 6 h, 18 h, 30 h, and 42 216 
h were 4.916 ± 0.11, 8.18 ± 0.14, 9.57 ± 0.20, 10.19 ± 0.11, the MEPM-treated group at 217 
18 h, 30 h, and 42 h were 5.06 ± 0.05, 4.55±0.33, and 6.38 ± 0.17, the AMK-treated group 218 
at 18 h, 30 h, and 42 h were 3.68 ± 0.10, 3.94 ± 0.05, and 6.17 ± 0.16, and in the 219 
MEPM+AMK-treated group at 18 h, 30 h, and 42 h were 3.20 ± 0.11, 2.74 ± 0.07, and 220 
2.00 ± 0.00, respectively. The bacterial load of the group receiving combination therapy 221 
at 30 h and 42 h (Fig. 3B, C) was statistically lower than that in each monotherapy group.  222 
The bacterial load in the blood was also counted and analyzed. The bacterial counts in the 223 
blood of the mice of control group, MEPM, AMK, and MEPM+AMK group were 6.12 ± 224 
0.46, 0.00 ± 0.00, 0.73 ± 0.73 and 0.00 ± 0.00, respectively (Fig. 3D). The bacterial counts 225 
in the lungs of the mice which received thorough course of antibiotic therapy were below 226 
the detection limit. 227 
 228 
3.5. Histopathological examinations 229 
Light microscopy analysis of the HE-stained lungs of the control group at 42 h post 230 
infection, revealed infiltration of large numbers of inflammatory cells in the alveolar 231 
spaces, alveolar hemorrhage, and destruction of alveolar structures (Fig. 4A). These 232 
findings are relatively conservative in the treatment groups. In MEPM+AMK-treated 233 
mice, only mild inflammatory changes were observed, supporting a beneficial advantage 234 
of using combination therapy.  235 
 236 
3.6. Analysis of BALF 237 
KP2 induced an increase in the total number of neutrophils in BALF. The total numbers 238 
of neutrophils in BALF were significantly lower in treatment groups, with significant 239 
reduction in the MEPM+AMK-treated group compared to MEPM or AMK monotherapy 240 
groups (Fig. 4B).  241 
 242 
  243 
4. Discussion 244 
In this study, we developed a novel CR-Kp mouse model of pneumonia using an agar-245 
based inoculum method. Furthermore, we demonstrated the efficacy of combination 246 
MEPM and AMK therapy in this model.  247 
To the best of our knowledge, this is the first study to establish a CR-Kp pneumonia model 248 
in immunocompetent mice. K. pneumoniae is one of the most common pathogens of 249 
community-acquired pneumonia, causing infection in immunocompetent patients [17–250 
19]. Therefore, in this study, the pneumonia mouse model under immunocompetent 251 
conditions is more relevant than the neutropenic mouse model commonly used for 252 
assumed patient populations. We generated this mouse model using an agar-based 253 
inoculum method that was previously reported [14]. Agar-based inoculum enables 254 
bacteria to scaffold in the lungs and helps their primary growth. Correspondingly, this 255 
method showed robust development of pneumonia with sufficient reproducibility. 256 
Furthermore, it has potential adaptability to other pneumonia mouse models, independent 257 
of bacterial strains or mouse matching. However, the concern remains that agar itself 258 
might induce some inflammatory response, regardless of the existence of an infection. 259 
Therefore, it may be difficult to precisely assess the host-pathogen interaction in this 260 
model. However, evidence of infectious inflammation is suggested by the continuous 261 
bacterial growth and findings of pathological bacterial infection observed (Fig. 1B, C). 262 
Additionally, no deaths were observed in mice exposed to agar-based inoculum without 263 
bacterial suspension. For these reasons, we consider this model appropriate in validating 264 
the efficacy of antimicrobial agents against pathogens.  265 
The efficacy of MEPM and AMK combination therapy against CR-Kp pneumonia over 266 
monotherapy was thoroughly demonstrated by this study. The number of viable bacteria 267 
in the lungs decreased and the inflammatory changes were limited in the combination 268 
therapy group when compared to those in the monotherapy groups. Several clinical 269 
studies have suggested the effectiveness of carbapenem and AMK in combination against 270 
CR-Kp pneumonia, [20,21] but little is known about the efficacy of the combination in 271 
vivo. Hirsch et al. screened combinations of doripenem, AMK, levofloxacin, or rifampin 272 
against CR-Kp in vitro and found that doripenem and AMK exerted a synergistic effect. 273 
[22] They further assessed the combination in immunocompromised mice and 274 
demonstrated its efficacy by comparing with a placebo control group. In this study, we 275 
demonstrated the superiority of the combination therapy to monotherapy in vivo. We 276 
consider these results to be meaningful, based on the findings in vitro and the supporting 277 
clinical evidence available. 278 
On the other hand, a certain degree of reduction in bacterial load and inflammatory cell 279 
infiltration were shown by both monotherapy groups. Furthermore, sufficient 280 
improvement of survival was observed in both monotherapy and combination treatment 281 
groups. These results can be partially explained by the immunocompetent status. In a 282 
meta-analysis comparing β-lactam monotherapy with β-lactam-aminoglycoside 283 
combination therapy for severe infections, no advantage of the combination therapy on 284 
mortality, in patients without neutropenia, was found [23]. Another review of clinical 285 
studies suggests that combination therapy is associated with improved outcomes only in 286 
severely ill patients. [24] These clinical data suggest that combination therapy contributes 287 
to survival rate improvement only in immunocompromised or severely ill patients; this 288 
finding is consistent with our results that even monotherapy improved survival rate in an 289 
immunocompetent host. 290 
There are several limitations to this study. First, we have not performed any 291 
pharmacokinetic analysis. Therefore, the drug administration doses are determined 292 
according to the previous studies in mice [15,16] and the intervals are set considering the 293 
half-life in mice, which is shorter than in humans [25]. In this study, antimicrobial effects 294 
were observed in each monotherapy treatment group, and the synergistic effects were 295 
confirmed for those situations. Further studies including PK studies are needed in order 296 
to confirm concordance between synergies in vitro and in vivo. Another limitation is that 297 
we assessed a single strain of KP2 in this study. We tried other clinical isolates, but the 298 
pathogenicity was weak, and it was difficult to create pneumonia stably. This KP2 strain 299 
possesses IMP-1 carbapenemase, which is the most dominant type in Japan [13]. It is 300 
known that different types of carbapenemase hydrolyze carbapenems to different degrees, 301 
thereby exhibiting variations in antimicrobial resistance [26]. For example, most of the 302 
strains harboring IMP-1 carbapenemase exhibit susceptibility to aminoglycosides [13], 303 
while NDM-1 carbapenemase possessing strains often show high levels of resistance 304 
against aminoglycosides [27]. Hence, careful attention is required in applying these 305 
results to clinical situations. In order to combat highly carbapenem-resistant pathogens, 306 
other antimicrobial combinations against various strains should be further explored and 307 
assessed. 308 
In conclusion, this pneumonia model is robust and consistent enough to evaluate 309 
antimicrobial effectiveness. We confirmed that combination therapy of MEPM and AMK 310 
was effective in the treatment of CR-Kp-induced pneumonia mouse model. Exploration 311 
of additional antimicrobial combinations for selection or to be avoided and further 312 
validation against other MIC strains is warranted.   313 
 314 
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  421 
Figure legends 422 
Figure 1. Evaluation of the CR-Kp mouse model of pneumonia. The effects of agar 423 
based inoculum of 103 and 104 CR-Kp/mouse on mouse survival (A, n=5). The number 424 
of viable bacteria in lungs over time (B, n=6). Pathological findings show inflammatory 425 
cell accumulation, hemorrhaging in the lungs, and alveolar destruction (C). 426 
 427 
Figure 2. Treatment effect on survival rate (A, n=7) and bodyweight changes (B, n=7). 428 
In bodyweight changes, the data are expressed as relative values, with day 0 429 
being 100%. *, P<0.05 vs. MEPM group; **, P<0.01 vs. MEPM group; ***, 430 
P<0.001 vs. MEPM group; †, P<0.05 vs. AMK group. 431 
 432 
Figure 3. Number of viable bacteria in lungs. Agar based inoculum of 104 CR-433 
Kp/mouse with antibiotic treatment initiated 6 h post infection. The bacterial load in the 434 
lungs (n=3 or 4 per group) was counted and analyzed at 18, 30, and 42 h post infection 435 
(A). At 30 h (B), and 42 h (C), combination therapy (MEPM+AMK) significantly 436 
reduced bacterial load when compared to each monotherapy. The bacterial load in the 437 
blood was counted and analyzed at 42 h post infection (D). All of the control mouse had 438 
bacteremia, bacteremia was not seen in the treatment groups, except for a few cases in 439 
the monotherapy groups. Data are representative of three independent experiments. 440 
*, P<0.05; ***, P<0.001; ****, P<0.0001. 441 
   442 
Figure 4. Histopathological examinations of the lungs of mice (A) and the total 443 
numbers of neutrophils in the BALF (B). At 42 h after infection, the control group and 444 
each treatment group were compared. Inflammatory cells infiltrating the alveolar 445 
spaces, alveolar hemorrhage and alveolar destruction were observed in the control 446 
group. Those findings were relatively limited in the treatment groups, and most limited 447 
in the combination treatment group. BALF analysis demonstrates a decrease in 448 
neutrophil counts in the treatment group, with significant reduction in the combination 449 


















A．Sequential bacterial load in lungs
B．Bacterial load in lungs at 30h post infection C．Bacterial load in lungs at 42h post infection D．Bacterial load in blood at 42h post infection
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